Table 2.
Examples of recent clinical trials utilizing FRα.
| Name of Intervention (Study ID) |
Years | Phase | Status |
|---|---|---|---|
| Technetium Tc 99m EC20 (NCT01689766) |
2003–2007 | Phase II | Completed |
| Folate receptor in stored plasma (NCT00787514) |
2008–2011 | Observational | Completed |
| Measurement of the folate receptor in blood (NCT00838747) | 2008–2011 | Observational | Completed |
| EC145 as a single-agent therapy and the combination of EC145 plus docetaxel versus docetaxel alone in participants with folate-receptor-positive [FR(++)] second-line NSCLC (NCT01577654) |
2011–2015 | Phase II | Completed |
| Mirvetuximab soravtansine (NCT01609556) |
2012–2018 | Phase I | Completed |
| Multi-epitope folate receptor alpha peptide vaccine (NCI-2012-00586) |
2012–2018 | Phase I | Completed |
| ONX-0801 (a novel α-folate-receptor-mediated thymidylate synthase inhibitor) (NCT02360345) |
2013–2021 | Phase I | Completed |
| Multi-epitope folate-receptor-alpha-loaded dendritic cell vaccine (NCT02111941) |
2014–2024 | Phase I | Active |
| OTL38 injection (OTL38) (NCT02317705) |
2014–2015 | Phase II | Completed |
| Mirvetuximab soravtansine (NCT02606305) |
2015–2021 | Phase I, II | Completed |
| Levels of soluble folate receptor and tumor-based folate receptor (NCT02520115) |
2015–2018 | Phase I | Completed |
| Folate receptor alpha peptide vaccine (NCT02593227) |
2016–2021 | Phase II | Completed |
| Mirvetuximab soravtansine (FORWARD I) (NCT02631876) |
2016–2020 | Phase III | Completed |
| Mov18 IgE (NCT02546921) | 2016–2021 | Phase I | Completed |
| TPIV200/huFR-1 (A multi-epitope anti-folate-receptor vaccine) (NCT02764333) |
2016–2021 | Phase II | Completed |
| [18F]-Azafol as a tracer in positron emission tomography (PET) in folate-receptor-positive cancer (NCT03242993) | 2017–2019 | Phase I | Completed |
| Farletuzumab ecteribulin (NCT03386942) |
2017–2022 | Phase I | Completed |
| Folate receptor alpha peptide vaccine with GM-CSF as a vaccine adjuvant following oral cyclophosphamide versus GM-CSF (NCT03012100) |
2017–2026 | Phase II | Active |
| OTL38 for injection (NCT02872701) |
2017–2018 | Phase II | Completed |
| OTL38 (NCT03180307) |
2018–2020 | Phase III | Completed |
| Mirvetuximab soravtansine (MIRV) (MIRASOL) (NCT04209855) |
2019–2024 | Phase III | Active |
| Mirvetuximab soravtansine (MIRV) (NCT04296890) |
2020–2022 | Phase III | Completed |
| OTL38 for injection (NCT04241315) |
2020–2021 | Phase III | Completed |
| Mirvetuximab soravtansine (MIRV) (PICCOLO) (NCT05041257) |
2021–2024 | Phase II | Active |
| ITIL-306 (NCT05397093) |
2022–2039 | Phase I | Active |